| RANK signaling blockade reduces breast cancer recurrence by inducing tumor cell differentiation G Yoldi, P Pellegrini, EM Trinidad, A Cordero, J Gomez-Miragaya, ... Cancer research 76 (19), 5857-5869, 2016 | 64 | 2016 |
| Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells C Gómez-Aleza, B Nguyen, G Yoldi, M Ciscar, A Barranco, ... Nature communications 11 (1), 6335, 2020 | 62 | 2020 |
| Expression profile of Eph receptors and ephrin ligands in healthy human B lymphocytes and chronic lymphocytic leukemia B-cells LM Alonso-C, EMA Trinidad, B de Garcillan, M Ballesteros, M Castellanos, ... Leukemia research 33 (3), 395-406, 2009 | 53 | 2009 |
| An impaired transendothelial migration potential of chronic lymphocytic leukemia (CLL) cells can be linked to ephrin-A4 expression EM Trinidad, M Ballesteros, J Zuloaga, A Zapata, LM Alonso-Colmenar Blood, The Journal of the American Society of Hematology 114 (24), 5081-5090, 2009 | 50 | 2009 |
| Alteration of medial-edge epithelium cell adhesion in two Tgf-β3 null mouse strains E Martínez-Sanz, A Del Río, C Barrio, J Murillo, E Maldonado, B Garcillán, ... Differentiation 76 (4), 417-430, 2008 | 50 | 2008 |
| Eph-ephrin bidirectional signaling comes into the context of lymphocyte transendothelial migration EM Trinidad, AG Zapata, LM Alonso-Colmenar Cell adhesion & migration 4 (3), 363-367, 2010 | 30 | 2010 |
| Rankl impairs lactogenic differentiation through inhibition of the prolactin/Stat5 pathway at midgestation A Cordero, P Pellegrini, A Sanz-Moreno, EM Trinidad, J Serra-Musach, ... Stem Cells 34 (4), 1027-1039, 2016 | 28 | 2016 |
| Chromosome 12p Amplification in Triple-Negative/BRCA1-Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin Sensitivity J Gomez-Miragaya, A Diaz-Navarro, R Tonda, S Beltran, L Palomero, ... Cancer research 79 (16), 4258-4270, 2019 | 21 | 2019 |
| In vitro manipulation of cleft palate connective tissue: setting the bases of a proposed new treatment E Resel, E Martínez-Sanz, I González, E Trinidad, B Garcillán, M Amorós, ... Journal of Surgical Research 138 (1), 111-120, 2007 | 18 | 2007 |
| RANKL inhibitors for osteosarcoma treatment: hope and caution EM Trinidad, E González-Suárez Annals of Translational Medicine 4 (24), 2016 | 10 | 2016 |
| EphrinA4 plays a critical role in α4 and αL mediated survival of human CLL cells during extravasation MA Flores, P Fortea, EM Trinidad, D García, G Soler, FJ Ortuño, ... Oncotarget 7 (30), 48481, 2016 | 5 | 2016 |
| RANK is a poor prognosis marker and a therapeutic target in ER‐negative postmenopausal breast cancer M Ciscar, EM Trinidad, G Perez‐Chacon, M Alsaleem, M Jimenez, ... EMBO Molecular Medicine 15 (4), e16715, 2023 | 1 | 2023 |
| RANK is an independent biomarker of poor prognosis in estrogen receptor-negative breast cancer and a therapeutic target in patient-derived xenografts M Ciscar, EM Trinidad, H Perez-Montoyo, M Alsaleem, ... bioRxiv, 2021.12. 13.470911, 2021 | 1 | 2021 |
| Abstract PS16-04: Denosumab as an enhancer of the immune infiltrate in hormone receptor-positive early breast cancer. Subgroup analysis from the D-Biomark window-of-opportunity … A Vethencourt, E Trinidad, E Dorca, A Petit, T Soler-Monsó, A Stradella, ... Cancer Research 84 (9_Supplement), PS16-04-PS16-04, 2024 | | 2024 |
| Denosumab as an immune modulator in HER2-negative early breast cancer: results of the window-of-opportunity D-BIOMARK clinical trial. A Vethencourt, EM Trinidad, E Dorca, A Petit, MT Soler-Monsó, M Ciscar, ... | | 2024 |
| 289P Results of the window-of-opportunity clinical trial D-BIOMARK: Study of biomarkers of the antitumor activity of denosumab and its role as a modulator of the immune … A Vethencourt, EM Trinidad, ED Duch, A Petit, MT Soler-Monsó, ... Annals of Oncology 34, S300, 2023 | | 2023 |
| First results of the randomized window of opportunity clinical trial D-Biomark: Immunomodulatory effect of denosumab in early breast cancer A Vethencourt, EM Trinidad, A Petit, MT Soler-Monso, CG Aleza, ... CANCER RESEARCH 82 (4), 2022 | | 2022 |
| Abstract P2-08-10: First results of the randomized window of opportunity clinical trial D-Biomark: Immunomodulatory effect of denosumab in early breast cancer A Vethencourt, EM Trinidad, A Petit, MT Soler-Monsó, CG Aleza, ... Cancer Research 82 (4_Supplement), P2-08-10-P2-08-10, 2022 | | 2022 |
| Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells C Gomez Aleza, B Nguyen, G Yoldi, M Ciscar, A Barranco, ... European Journal Of Immunology 51, 239-239, 2021 | | 2021 |
| 14P Immunomodulatory effect of denosumab in early breast cancer: Preliminary results of a randomized window-opportunity clinical trial D-Biomark AC Vethencourt, EM Trinidad, CG Aleza, SP Simon, A Petit, T Soler, ... Annals of Oncology 32, S26, 2021 | | 2021 |
